McKesson Corporation (NYSE:MCK) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 10, Deutsche ...

If you are wondering whether McKesson still looks attractive after its strong run, or whether much of the potential upside is ...

McKesson saw strong 2025 growth from GLP-1 tailwinds, but fading momentum, weak margins, and a 21x forward P/E show ...

McKesson trades at $825.38 and has moved in lockstep with the market. Its shares have returned 14.5% over the last six months ...

McKesson (MCK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Healthcare giant McKesson Corp. on Tuesday said it will spin off its Technology Solutions unit and merge it with revenue cycle company Change Healthcare, creating a yet-to-be named healthcare services ...

Deal Rationale McKesson’s strategic focus on disciplined portfolio management involves continuous evaluation of its business segments to ensure alignment with its growth priorities and optimize ...

Healthcare services company McKesson has signed a definitive agreement to acquire a controlling interest in Community Oncology Revitalization Enterprise Ventures (Core Ventures) for about $2.49 ...

Discover why McKesson (MCK) is a Buy: strong revenue, margin gains, and robust capital returns suggest 13.5% upside. Click here to read my most recent analysis.

McKesson Corporation is a major pharmaceutical distributor that offers health care supply chain management, retail pharmacy, oncology, specialty care and health care information technology services.

In October, we joined forces with the Washington Post and reported a disturbing story of Washington at its worst - about an act of Congress that crippled the DEA's ability to fight the worst drug ...